Balchem earnings reached quarterly records in the third quarter of 2026, with net sales rising 6% year over year to $290.7 million. The specialty ingredients company announced the results on October 23 for the quarter ended September 30, reporting growth in sales and operating earnings across all three business segments.
Key Takeaways
- Net sales, net earnings and adjusted EBITDA reached consolidated quarterly records.
- Sales grew 6%, while adjusted EBITDA increased 4% from a year earlier.
- All three reporting segments delivered higher sales and operating earnings.
Table of Contents
- Balchem earnings reach records, but growth rates differ
- Growth extends across all three businesses
- Cash generation accompanies share repurchases
- Conclusion
Balchem earnings reach records, but growth rates differ
Balchem reported net earnings of $46.7 million and adjusted earnings before interest, taxes, depreciation and amortization of $80.3 million. Although both were quarterly records, the company reported net earnings growth of 0% at its stated precision, compared with a 4% increase in adjusted EBITDA.
The figures in Balchem’s third-quarter 2026 financial results show that record totals did not translate into equally strong growth across every measure. Sales increased faster than adjusted EBITDA, while reported net earnings were broadly unchanged from the prior-year quarter.
Adjusted EBITDA and adjusted earnings per share are non-GAAP measures and should be distinguished from the company’s GAAP profit figures.
| Item | Details |
|---|---|
| GAAP earnings per share | $1.46, versus $1.24 in the prior-year quarter. |
| Adjusted earnings per share | $1.57, versus $1.35 in the prior-year quarter. |
| Operating cash flow | $69.8 million in Q3 2026. |
| Free cash flow | $57.9 million in Q3 2026; a non-GAAP measure. |
| Common-stock repurchases | Approximately $28 million during the quarter and $127 million over the trailing 12 months. |
Growth extends across all three businesses
Chairman, President and Chief Executive Ted Harris said the quarter brought healthy growth across Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. Each segment increased both sales and earnings from operations.
Balchem serves nutrition, food, pharmaceutical and industrial markets. Its products include choline nutrients, mineral amino acid chelates, encapsulated ingredients and specialty gases used in medical-device sterilization.
The company also plans to showcase Human Nutrition and Health technologies at the upcoming SupplySide Global trade show, including science supporting its nutrient brands and developments in performance nutrition and functional food and beverage applications.
Cash generation accompanies share repurchases
Balchem generated positive operating and free cash flow while continuing to repurchase common stock. The company described the purchases as part of its balanced capital allocation strategy.
The per-share results, cash figures and repurchase totals provide additional measures of the quarter beyond consolidated sales and profit.
Conclusion
Balchem’s record quarter combined broad segment growth with slower increases in consolidated profit measures. Management scheduled an October 23, 2026, earnings call at 11 a.m. Eastern Time to review the results, providing the next confirmed opportunity for further detail.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
